785 articles
Clene's ALS therapy CNM-Au8 may qualify for FDA accelerated approval using a blood biomarker as a surrogate endpoint — a potential breakthrough for patients.
A new webinar tackles the real question in NAD+ supplementation: whether pills, injections, or pens produce meaningfully different health outcomes.
Recent NIH-funded studies map pancreatic cells, improve heart risk prediction, and reveal testosterone's role in brain tumors.
Three NIH-funded studies this week tackle metabolic decline, cardiac risk, and brain tumors — all with aging implications.
New cohort data revises assumptions about US life expectancy gaps, showing near-universal gains for those born 1941–2000.
A large clinical trial finds baduanjin, a gentle 800-year-old Chinese practice, lowers blood pressure comparably to medication and brisk walking.
A landmark European cardiology consensus links high UPF consumption to dramatically higher risks of heart disease, atrial fibrillation, and early death.
New research reveals fructose acts as a metabolic signal promoting fat storage, insulin resistance, and chronic disease risk.
Enpatoran cut lupus skin severity scores by up to 72% vs 44% for placebo, with phase III trials now underway.
A pilot trial found tailored DASH coaching plus produce prescriptions slashed systolic BP by 13 mmHg in adherent adults with uncontrolled hypertension.
New research finds GLP-1 receptor agonists may dramatically cut age-related macular degeneration risk compared to other medications.
The FDA extended its priority review for a weekly injectable Alzheimer's drug by three months, with no approvability concerns raised.
